Jump to full article: Reuters, 2009-11-16
Intro: * Nabi to get $40 mln upfront, total potential of $500 mln
* Deal expected to complete in Q1, 2010
* Nabi shares jump 26 pct (Adds details, share movement)
Nov 16 (Reuters) - Nabi Biopharmaceuticals (NABI.O) and a unit of GlaxoSmithKline Plc (GSK.L) signed a licensing agreement for Nabi's experimental vaccine to treat nicotine addiction and the prevention of smoking relapse, the companies said, sending Nabi shares up 26 percent.
Jump to full article » |